Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | F2 | P00734 | 2/20 | 0.54 |
| ▸ | PLAU | P00749 | 2/20 | 0.54 |
| ▸ | ELANE | P08246 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25209653 | 0.84 | MGAM (0.51) | HSP90AA1F2PLAUELANEGAA | |
| SCHEMBL2120160 | 0.83 | HSP90AA1 (0.47) | HSP90AA1F2PLAUELANEGAA | |
| SCHEMBL15007112 | 0.83 | MAPT (0.54) | HSP90AA1F2PLAUELANEGAA | |
| SCHEMBL15412508 | 0.83 | MGAM (0.53) | HSP90AA1F2PLAUELANEGAA | |
| SCHEMBL22518629 | 0.83 | MGAM (0.53) | HSP90AA1F2PLAUELANEGAA | |
| SCHEMBL30729451 | 0.81 | ALDH1A1 (0.51) | HSP90AA1F2PLAUELANEGAA | |
| SCHEMBL22633155 | 0.81 | KEAP1 (0.56) | HSP90AA1F2PLAUELANEGAA | |
| SCHEMBL26696761 | 0.81 | HSP90AA1 (0.48) | HSP90AA1F2PLAUELANEGAA | |
| SCHEMBL16799807 | 0.81 | KEAP1 (0.59) | HSP90AA1F2PLAUELANEMAPT | |
| SCHEMBL12819078 | 0.80 | MGAM (0.51) | HSP90AA1GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0200872-B1 | HERBICIDAL AND INSECTICIDAL AGENT BASED ON PYRAZOL DERIVATIVES | BAYER AG (DE) | 1990-04-18 | — | — | EP | claimed |
| CN-1030410-A | The N-phenylpyrazole derivatives | MAY & BAKER LTD (GB) | 1989-01-18 | — | — | CN | claimed |
| EP-0295118-A1 | N-phenylpyrazole derivatives | RHONE-POULENC AGRICULTURE LIMITED (GB) | 1988-12-14 | — | — | EP | claimed |
| US-4746354-A | PRE- AND POSTEMERGENCE | BAYER AKTIENGESELLSCHAFT (DE) | 1988-05-24 | — | — | US | claimed |
| EP-0200872-A1 | Herbicidal and insecticidal agent based on pyrazol derivatives | BAYER AG (DE) | 1986-11-12 | — | — | EP | claimed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2025038863-A1 | INDOLE AND PYRROLOYPYRIDINE DERIVATIVES AS GPR17 MODULATORS | BIOGEN MA INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240182475-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH HYPERMINERALIZATION | Université de Lausanne (CH) | 2024-06-06 | — | — | US | disclosed |
| EP-4308117-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH HYPERMINERALIZATION | Université de Lausanne (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-116987080-A | Macrocyclic compounds with heterocyclic P2' groups as factor XIA inhibitors | 百时美施贵宝公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-1030410-A | The N-phenylpyrazole derivatives | MAY & BAKER LTD (GB) | 1989-01-18 | — | — | CN | disclosed |
| EP-0295118-A1 | N-phenylpyrazole derivatives | RHONE-POULENC AGRICULTURE LIMITED (GB) | 1988-12-14 | — | — | EP | disclosed |
| EP-0295118-A1 | N-phenylpyrazole derivatives | RHONE-POULENC AGRICULTURE LIMITED (GB) | 1988-12-14 | — | — | EP | disclosed |
| US-4746354-A | PRE- AND POSTEMERGENCE | BAYER AKTIENGESELLSCHAFT (DE) | 1988-05-24 | — | — | US | disclosed |
| US-4746354-A | PRE- AND POSTEMERGENCE | BAYER AKTIENGESELLSCHAFT (DE) | 1988-05-24 | — | — | US | disclosed |
| US-4746354-A | PRE- AND POSTEMERGENCE | BAYER AKTIENGESELLSCHAFT (DE) | 1988-05-24 | — | — | US | disclosed |
| EP-0200872-A1 | Herbicidal and insecticidal agent based on pyrazol derivatives | BAYER AG (DE) | 1986-11-12 | — | — | EP | disclosed |
| EP-0200872-A1 | Herbicidal and insecticidal agent based on pyrazol derivatives | BAYER AG (DE) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182475-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH HYPERMINERALIZATION | CTH, CBS, GAA | HSP90AA1 1243/4885F2 1885/4885PLAU 400/4885 |
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F2 | HSP90AA1 4626/4885F2 3/4885PLAU 24/4885 |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | HSP90AA1 3675/4885F2 1982/4885PLAU 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.